CD274 and small cell lung carcinoma: Recently, the CAPSTONE‐1 study showed that adebrelimab (a novel anti‐PD‐L1 inhibitor) combined with chemotherapy significantly prolonged the OS in ES‐SCLC with a tolerable safety profile.23